Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Press releases
Abliva arranges Mitochondria Day on 16 September 2020 – preliminary program
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Abliva – Virtual Capital Markets Day today at 3.00 p.m.
Abliva AB (Nasdaq Stockholm: ABLI) – today, 23 June 2020, holds a virtual Capital Markets Day. The theme of the day will be the company's new strategic focus on primary mitochondrial disease, the most ...
Abliva arranges virtual Capital Markets Day on 23 June
Abliva AB (Nasdaq Stockholm: ABLI), invites to a virtual capital markets day on 23 June at 3.00 - 4.30 p.m. CEST. The theme of the day will be the company's new strategic focus on primary mitochondria ...
NeuroVive Pharmaceutical changes its name to Abliva
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) announced today that the company’s application for a change of name to Abliva AB (publ) has been approved by the Swedish Companies Registration Offi ...